1. AbCellera will announce Q2 2025 results on August 7. 2. Earnings call scheduled for 2:00 p.m. PT, accessible via webcast. 3. The company develops antibody medicines across various therapeutic areas. 4. AbCellera aims for first-in-class programs and collaborations for drug development.
Earnings calls typically suggest investor transparency. If results exceed expectations, ABCL's stock may experience upward pressure.
Earnings results will impact investor sentiment and perceived value of ABCL.
Earnings results are immediate catalysts for market reaction, affecting ABCL's stock quickly.
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) will announce its second quarter 2025 financial results on Thursday, August 7, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference call.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.